The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics
The DOI matches its Crossref record; 157 of the 157 references it cites were found in a registry or an index.
Abstract
The amyloid cascade hypothesis, which posits that the deposition of the amyloid-β peptide in the brain is a central event in Alzheimer's disease pathology, has dominated research for the past twenty years. Several therapeutics that were purported to reduce amyloid-β production or aggregation have failed in Phase III clinical testing, and many others are in various stages of development. Therefore, it is timely to review the science underpinning the amyloid cascade hypothesis, consider what type of clinical trials will constitute a valid test of this hypothesis and explore whether amyloid-β-directed therapeutics will provide the medicines that are urgently needed by society for treating this devastating disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Pathogenetic studies have shown that Aβ peptide accumulation in the brain is an early and central event, 2”
From Amyloid Plaque Imaging with a Targeted MRI Contrast Agent in a Transgenic Mouse Model of Alzheimer’s Disease (2022) · cites this paper as [2]
In the citing paper
“One possible resolution is that amyloid pathology acts only as a trigger in sporadic AD (Karran et al., 2011); i.e., Aβ accumulation is necessary but insufficient to cause full-blown disease.”
From The Major Risk Factors for Alzheimer’s Disease: Age, Sex, and Genes Modulate the Microglia Response to Aβ Plaques (2019) · cites this paper as Karran et al., 2011
In the citing paper
“since it is known that the Aβ plaques act as a driver of AD pathology63 and the accumulation Aβ plaques in the brain initiates a complex multicellular neurodegenerative process.”
From Interferon signaling modulates Down syndrome-associated Alzheimer’s disease pathology in a mouse model (2025) · cites this paper as [63]
In the citing paper
“The amyloid cascade hypothesis, which dominated the field for over three decades, proposed that the abnormal accumulation of Aβ initiates a downstream cascade leading to tau hyperphosphorylation, synaptic dysfunction, and neuronal death [6, 7].”
From Toward a Unified Framework in Molecular Neurobiology of Alzheimer’s Disease: Revisiting the Pathophysiological Hypotheses (2026) · cites this paper as [7]
In the citing paper
“a possible cause of clinical failure could be the difficulty of inhibiting these proteinases without causing side effects resulting from non-targeted proteolytic inhibition on their many physiological substrates”
From Emerging Alternative Proteinases in APP Metabolism and Alzheimer’s Disease Pathogenesis: A Focus on MT1-MMP and MT5-MMP (2019) · cites this paper as Karran et al., 2011
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
RetractedMcKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429 · cited 1×
“The apolipoprotein E ( APOE ) gene represents the major genetic risk factor for A”
BackgroundAlzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659 · cited 1×
“The discovery that AD could be inherited in an autosomal dominant fashio”
Background
Research works printed but not linked: 2
- Burns, A. & Ilife, S. Dementia. BMJ 338, 405–409 (2009).
- Alzheimer, A. About a peculiar disease of the cerebral cortex. [in German] Centralblatt für Nervenheilkunde Psychiatrie 30, 177–179 (1907).
Cited by
Items 101–200 of 1,007
Challenges for Alzheimer's Disease Therapy: Insights from Novel Mechanisms Beyond Memory Defects
Frozza, R. L., Lourenco, M. V., & De Felice, F. G. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00037 · Cited by 198
“These constraints may be due to that clinical trials have predominantly focused on therapies based on anti-amyloid strategies, since the amyloid cascade hypothesis has been placed at the center of therapeutic prospection (Karran et al., 2011; Cummings et al., 2014; Hendrix et al., 2016).”
BackgroundJi, M., Arbel, M., Zhang, L., Freudiger, C. W., Hou, S. S., Lin, D., Yang, X., Bacskai, B. J., & Xie, X. S. (2018) · Science Advances · doi:10.1126/sciadv.aat7715 · Cited by 197
Farina, N., Rusted, J., & Tabet, N. (2014) · International Psychogeriatrics · doi:10.1017/s1041610213001385 · Cited by 195
“Cognitive decline in AD is attributable at least in part to the buildup of amyloid and tau proteins, which promote neuronal dysfunction and death (Hardy and Selkoe, 2002; Karran et al., 2011).”
BackgroundAhmad, M. H., Fatima, M., & Mondal, A. C. (2019) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2018.10.034 · Cited by 191
Grouleff, J., Irudayam, S. J., Skeby, K. K., & Schiøtt, B. (2015) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2015.03.029 · Cited by 192
Multitarget therapeutic strategies for Alzheimer’s disease
Gabr, M., & Ibrahim, M. (2019) · Neural Regeneration Research · doi:10.4103/1673-5374.245463 · Cited by 190
“The progression of Alzheimer’s (AD) is directly correlated to the deposition of amyloid-β peptides in the human brain as mature fibrils according to the amyloid cascade hypothesis (Karran et al., 2011).”
Glutamate and GABA in Microglia-Neuron Cross-Talk in Alzheimer’s Disease
Czapski, G. A., & Strosznajder, J. B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111677 · Cited by 191
Goure, W. F., Krafft, G. A., Jerecic, J., & Hefti, F. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt272 · Cited by 190
“Because bapineuzumab binds monomeric Aβ with similar affinity to soluble Aβ oligomers and fibrillar Aβ and because Aβ soluble oligomer levels are orders of magnitude less than Aβ monomer and fibrils levels in the AD brain [58-65], it is clear that bapineuzumab was not dosed high enough in the pivotal phase 3 trials to…”
BackgroundLiu, Y., An, S., Li, J., Kuang, Y., He, X., Guo, Y., Ma, H., Zhang, Y., Ji, B., & Jiang, C. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2015.11.060 · Cited by 188
“On one hand, the complex pathology of brain diseases usually involves more than one pathway dysfunctions [6,7], requiring co-delivery of multiple drugs to achieve the synergetic effects.”
BackgroundThomas, M. P., Mills, S. J., & Potter, B. V. L. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201502227 · Cited by 188
Long, J. M., Ray, B., & Lahiri, D. K. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.518241 · Cited by 187
“From a molecular viewpoint, the disease is thought to arise in part from excess deposition of the amyloid- peptide (A ) (4, 5).”
BackgroundAn aberrant sugar modification of BACE1 blocks its lysosomal targeting in Alzheimer's disease
Kizuka, Y., Kitazume, S., Fujinawa, R., Saito, T., Iwata, N., Saido, T. C., Nakano, M., Yamaguchi, Y., Hashimoto, Y., Staufenbiel, M., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404438 · Cited by 185
“Deposition of amyloid-b (Ab) peptide in the brain is considered to represent the initial event in disease development (Karran et al, 2011).”
BackgroundVitamin D in Neurological Diseases: A Rationale for a Pathogenic Impact
Moretti, R., Morelli, M. E., & Caruso, P. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082245 · Cited by 186
“Similarly, the benefit of vitamin D supplementation for stroke-related depressive symptoms is still being debated [156].”
Backgroundβ-arrestin 2 regulates Aβ generation and γ-secretase activity in Alzheimer's disease
Thathiah, A., Horré, K., Snellinx, A., Vandewyer, E., Huang, Y., Ciesielska, M., De Kloe, G., Munck, S., & De Strooper, B. (2013) · Nature Medicine · doi:10.1038/nm.3023 · Cited by 185
Self-citationMitochondrial cholesterol: Metabolism and impact on redox biology and disease
Goicoechea, L., Conde de la Rosa, L., Torres, S., García-Ruiz, C., & Fernández-Checa, J. C. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102643 · Cited by 181
“The hippocampus is the brain area responsible for memory, and hence, this area is particularly vulnerable in AD and shows extensive neuronal loss [130].”
BackgroundMitochondrial dysfunction: the missing link between aging and sporadic Alzheimer’s disease
Grimm, A., Friedland, K., & Eckert, A. (2016) · Biogerontology · doi:10.1007/s10522-015-9618-4 · Cited by 182
“The ''Amyloid cascade hypothesis'' has prevailed in the AD field for more than 20 years, and is still leading drug development strategies (Castello and Soriano 2014; Karran et al. 2011).”
BackgroundAmyloid cascade in Alzheimer's disease: Recent advances in medicinal chemistry
Mohamed, T., Shakeri, A., & Rao, P. P. N. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.02.049 · Cited by 180
Ackley, S. F., Zimmerman, S. C., Brenowitz, W. D., Tchetgen Tchetgen, E. J., Gold, A. L., Manly, J. J., Mayeda, E. R., Filshtein, T. J., Power, M. C., Elahi, F. M., et al. (2021) · BMJ · doi:10.1136/bmj.n156 · Cited by 174
Sproul, A. A., Jacob, S., Pre, D., Kim, S. H., Nestor, M. W., Navarro-Sobrino, M., Santa-Maria, I., Zimmer, M., Aubry, S., Steele, J. W., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0084547 · Cited by 162
“The most prevalent theory for the underlying cause of AD is the ‘‘amyloid hypothesis’’, in which toxic oligomerogenic forms of Ab, a cleavage product of APP, accumulate and cause neuronal dysfunction and cell death [4].”
BackgroundCerebrospinal fluid neurogranin and YKL ‐40 as biomarkers of Alzheimer's disease
Janelidze, S., Hertze, J., Zetterberg, H., Landqvist Waldö, M., Santillo, A., Blennow, K., & Hansson, O. (2016) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.266 · Cited by 179
“Disappointingly, however, phase III clinical trials in patients with moderate to mild disease have failed to show clinical benefit of drugs reducing Ab plaque burden.(2) The failure has been partly attributed to the fact that new therapies were initiated in the late stages of the disease and to the relatively high rat…”
BackgroundIturria-Medina, Y., Sotero, R. C., Toussaint, P. J., Evans, A. C., & Initiative, A. T. A. D. N. (2014) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003956 · Cited by 175
“For decades, Aß propagation and accumulation has been thought to have a causal role on the cascade of cognitive/ clinical events leading to AD [52], [53].”
BackgroundVitamin k3 inhibits protein aggregation: Implication in the treatment of amyloid diseases
Alam, P., Chaturvedi, S. K., Siddiqi, M. K., Rajpoot, R. K., Ajmal, M. R., Zaman, M., & Khan, R. H. (2016) · Scientific Reports · doi:10.1038/srep26759 · Cited by 176
Antioxidant gene therapy against neuronal cell death
Navarro-Yepes, J., Zavala-Flores, L., Anandhan, A., Wang, F., Skotak, M., Chandra, N., Li, M., Pappa, A., Martinez-Fong, D., Del Razo, L. M., et al. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.12.007 · Cited by 176
“It is important to state that amyloid-independent mechanisms have also been proposed to contribute to AD (Karran et al., 2011; Pimplikar et al., 2010).”
Scott, J. D., Li, S. W., Brunskill, A. P. J., Chen, X., Cox, K., Cumming, J. N., Forman, M., Gilbert, E. J., Hodgson, R. A., Hyde, L. A., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00307 · Cited by 174
Circadian and sleep dysfunction in Alzheimer’s disease
Uddin, M. S., Tewari, D., Mamun, A. A., Kabir, M. T., Niaz, K., Wahed, M. I. I., Barreto, G. E., & Ashraf, G. M. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101046 · Cited by 173
Graphene quantum dots conjugated neuroprotective peptide improve learning and memory capability
Xiao, S., Zhou, D., Luan, P., Gu, B., Feng, L., Fan, S., Liao, W., Fang, W., Yang, L., Tao, E., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.08.021 · Cited by 169
“[4] Karran E, Mercken M, De Strooper B.”
BackgroundHeat shock proteins as potential targets for protective strategies in neurodegeneration
Kampinga, H. H., & Bergink, S. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00099-5 · Cited by 172
Modifications and Trafficking of APP in the Pathogenesis of Alzheimer’s Disease
Wang, X., Zhou, X., Li, G., Zhang, Y., Wu, Y., & Song, W. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00294 · Cited by 172
“…fibrils do, indicating that reducing Aβ generation, facilitating Aβ clearance and blocking Aβ oligomerization would be potential strategies to inhibit the pathogenesis of AD (Sun et al., 2006a; Walsh and Selkoe, 2007; Qing et al., 2008; Karran et al., 2011; Ly et al., 2013; Dong et al., 2015).”
BackgroundHighlights in BACE1 Inhibitors for Alzheimer's Disease Treatment
Coimbra, J. R. M., Marques, D. F. F., Baptista, S. J., Pereira, C. M. F., Moreira, P. I., Dinis, T. C. P., Santos, A. E., & Salvador, J. A. R. (2018) · Frontiers in Chemistry · doi:10.3389/fchem.2018.00178 · Cited by 171
“The “Amyloid Cascade Hypothesis” proposes that the cerebral appearance of aggregates of oligomeric Aβ plays a central role for AD neuropathogenicity (Karran et al., 2011; Selkoe and Hardy, 2016).”
BackgroundProtein-Capped Metal Nanoparticles Inhibit Tau Aggregation in Alzheimer’s Disease
Sonawane, S. K., Ahmad, A., & Chinnathambi, S. (2019) · ACS Omega · doi:10.1021/acsomega.9b01411 · Cited by 166
“14 The target-based research has yielded a number of candidates against amyloid-β 15 and Tau pathology but with little success in the higher clinical trials.”
Secondary nucleation and elongation occur at different sites on Alzheimer’s amyloid-β aggregates
Scheidt, T., Łapińska, U., Kumita, J. R., Whiten, D. R., Klenerman, D., Wilson, M. R., Cohen, S. I. A., Linse, S., Vendruscolo, M., Dobson, C. M., et al. (2019) · Science Advances · doi:10.1126/sciadv.aau3112 · Cited by 164
“Klenerman, The extracellular chaperone clusterin sequesters oligomeric forms of the amyloid-b(1-40) peptide.”
The Unfolded Protein Response and the Role of Protein Disulfide Isomerase in Neurodegeneration
Perri, E. R., Thomas, C. J., Parakh, S., Spencer, D. M., & Atkin, J. D. (2016) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2015.00080 · Cited by 164
Crimins, J. L., Pooler, A., Polydoro, M., Luebke, J. I., & Spires-Jones, T. L. (2013) · Ageing Research Reviews · doi:10.1016/j.arr.2013.03.002 · Cited by 163
Zhao, Y., Cai, J., Liu, Z., Li, Y., Zheng, C., Zheng, Y., Chen, Q., Chen, H., Ma, F., An, Y., et al. (2019) · Nano Letters · doi:10.1021/acs.nanolett.8b03644 · Cited by 162
Targeting Autophagy for the Treatment of Alzheimer’s Disease: Challenges and Opportunities
Liu, J., & Li, L. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00203 · Cited by 162
“Abnormally high levels of Aβ, ubiquitinated proteins, and LC3-II are presented in the lysosome and AVs fractions isolated from the brains of TgCRND8 mice (Yang et al., 2011b).”
BackgroundMethodInfluentialBourgade, K., Le Page, A., Bocti, C., Witkowski, J. M., Dupuis, G., Frost, E. H., & Fülöp, T. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150652 · Cited by 161
“However, both forms are characterized by similar pathological changes namely, irreversible neuronal loss, deposits of cortical senile plaques and neurofibrillary tangles in the brain of affected patients [6, 7].”
BackgroundMicroglia activation states and cannabinoid system: Therapeutic implications
Mecha, M., Carrillo-Salinas, F. J., Feliú, A., Mestre, L., & Guaza, C. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.06.011 · Cited by 159
“This led to the postulation of the “inflammatory cascade hypothesis of AD”, whereby Aβ deposition could induce neuroinflammation, which in turn generates more Aβ and sets off a vicious circle that promotes both neurodegeneration and inflammation (Karran et al., 2011).”
BackgroundIwata, A., Nagata, K., Hatsuta, H., Takuma, H., Bundo, M., Iwamoto, K., Tamaoka, A., Murayama, S., Saido, T., & Tsuji, S. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddt451 · Cited by 157
The circular RNA ci RS‐7 promotes APP and BACE 1 degradation in an NF‐κB‐dependent manner
Shi, Z., Chen, T., Yao, Q., Zheng, L., Zhang, Z., Wang, J., Hu, Z., Cui, H., Han, Y., Han, X., et al. (2017) · The FEBS Journal · doi:10.1111/febs.14045 · Cited by 157
The mutational landscape of a prion-like domain
Bolognesi, B., Faure, A. J., Seuma, M., Schmiedel, J. M., Tartaglia, G. G., & Lehner, B. (2019) · Nature Communications · doi:10.1038/s41467-019-12101-z · Cited by 158
Végh, M. J., Heldring, C. M., Kamphuis, W., Hijazi, S., Timmerman, A. J., Li, K., van Nierop, P., Mansvelder, H. D., Hol, E. M., Smit, A. B., et al. (2014) · Acta Neuropathologica Communications · doi:10.1186/preaccept-1259006781131998 · Cited by 83
“Increased production or reduced clearance of Aβ is considered a prerequisite for the neuropathological and clinical manifestation of AD [2,3].”
BackgroundOxidative stress, cellular senescence and ageing
Pole, A., Department of Biochemistry and Molecular Medicine, S. O. M. A. H. S., Dimri, M., & P. Dimri, G. (2016) · AIMS Molecular Science · doi:10.3934/molsci.2016.3.300 · Cited by 155
“plaque, which interferes with neuronal communication and potentially initiates AD progression [135].”
BackgroundAPOE4-mediated amyloid-β pathology depends on its neuronal receptor LRP1
Tachibana, M., Holm, M.-L., Liu, C.-C., Shinohara, M., Aikawa, T., Oue, H., Yamazaki, Y., Martens, Y. A., Murray, M. E., Sullivan, P. M., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci124853 · Cited by 156
Passive immunotherapies targeting Aβ and tau in Alzheimer's disease
Plotkin, S. S., & Cashman, N. R. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105010 · Cited by 155
Animal models of Alzheimer’s disease: Applications, evaluation, and perspectives
Chen, Z.-Y., 北京大学生命科学学院膜生物学国家重点实验室, 北. 1., State Key Laboratory of Membrane Biology, C. O. L. S., & Zhang, Y. (2022) · Zoological Research · doi:10.24272/j.issn.2095-8137.2022.289 · Cited by 155
“The different categories of mutations have different effects on AβPP processing and the development of AD (Karran et al., 2011).”
McKenzie, A. T., Moyon, S., Wang, M., Katsyv, I., Song, W.-M., Zhou, X., Dammer, E. B., Duong, D. M., Aaker, J., Zhao, Y., et al. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0219-3 · Cited by 154
“Our OL-enriched consensus module includes genes encoding proteins associated with Aβ-production PSEN1 and BACE1, as well as the AD risk factor genes BIN1, PSEN1, PICALM, and UNC5C [27–30].”
InfluentialAutoregulated paracellular clearance of amyloid-β across the blood-brain barrier
Keaney, J., Walsh, D. M., O’Malley, T., Hudson, N., Crosbie, D. E., Loftus, T., Sheehan, F., McDaid, J., Humphries, M. M., Callanan, J. J., et al. (2015) · Science Advances · doi:10.1126/sciadv.1500472 · Cited by 153
The evolution of amidine-based brain penetrant BACE1 inhibitors
Oehlrich, D., Prokopcová, H., & Gijsen, H. J. M. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.03.025 · Cited by 163
Arginase 1+ microglia reduce Aβ plaque deposition during IL-1β-dependent neuroinflammation
Cherry, J. D., Olschowka, J. A., & O’Banion, M. K. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0411-8 · Cited by 152
“mation, leading to a vicious cycle that promotes AD pathogenesis [2].”
BackgroundSalloway, S., Honigberg, L. A., Cho, W., Ward, M., Friesenhahn, M., Brunstein, F., Quartino, A., Clayton, D., Mortensen, D., Bittner, T., et al. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0424-5 · Cited by 151
Ottoy, J., Niemantsverdriet, E., Verhaeghe, J., De Roeck, E., Struyfs, H., Somers, C., wyffels, L., Ceyssens, S., Van Mossevelde, S., Van den Bossche, T., et al. (2019) · NeuroImage: Clinical · doi:10.1016/j.nicl.2019.101771 · Cited by 151
“AD is of utmost importance to accurately identify at-risk subjects for enrichment of disease-modifying treatment trials (Karran et al., 2011).”
Alzheimer’s disease: How metal ions define β-amyloid function
Kepp, K. P. (2017) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2017.05.007 · Cited by 150
Sleep Disorders Associated With Alzheimer's Disease: A Perspective
Brzecka, A., Leszek, J., Ashraf, G. M., Ejma, M., Ávila-Rodriguez, M. F., Yarla, N. S., Tarasov, V. V., Chubarev, V. N., Samsonova, A. N., Barreto, G. E., et al. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00330 · Cited by 149
“The primary event in AD is the accumulation of amyloidβ (Aβ) in the brain (Karran et al., 2011).”
BackgroundKim, B., Kim, S., Nam, Y., Park, Y., Shin, S. M., & Moon, M. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00465-w · Cited by 187
Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications
Shih, H.-P., Zhang, X., & Aronov, A. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.194 · Cited by 160
Cogswell, P. M., Barakos, J. A., Barkhof, F., Benzinger, T. S., Jack, C. R., Poussaint, T. Y., Raji, C. A., Ramanan, V. K., & Whitlow, C. T. (2022) · American Journal of Neuroradiology · doi:10.3174/ajnr.a7586 · Cited by 144
“Ab removal for treatment of AD is based on the amyloid cascade hypothesis.(11) This model proposes that amyloid plaque deposition facilitates downstream pathophysiologic events including tau phosphorylation, neurofibrillary tangle formation, microglial activation, and eventually neurodegeneration and progressive cogni…”
Decreased amyloid-β and increased neuronal hyperactivity by immunotherapy in Alzheimer's models
Busche, M. A., Grienberger, C., Keskin, A. D., Song, B., Neumann, U., Staufenbiel, M., Förstl, H., & Konnerth, A. (2015) · Nature Neuroscience · doi:10.1038/nn.4163 · Cited by 158
Price, B. R., Sudduth, T. L., Weekman, E. M., Johnson, S., Hawthorne, D., Woolums, A., & Wilcock, D. M. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01915-0 · Cited by 146
Mansuroglu, Z., Benhelli-Mokrani, H., Marcato, V., Sultan, A., Violet, M., Chauderlier, A., Delattre, L., Loyens, A., Talahari, S., Bégard, S., et al. (2016) · Scientific Reports · doi:10.1038/srep33047 · Cited by 146
Millan, M. J. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.03.004 · Cited by 153
Bile acids: a communication channel in the gut-brain axis
Monteiro-Cardoso, V. F., Corlianò, M., & Singaraja, R. R. (2021) · NeuroMolecular Medicine · doi:10.1007/s12017-020-08625-z · Cited by 145
Benilova, I., Gallardo, R., Ungureanu, A.-A., Castillo Cano, V., Snellinx, A., Ramakers, M., Bartic, C., Rousseau, F., Schymkowitz, J., & De Strooper, B. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.599027 · Cited by 145
“This reinforces the amyloid hypothesis of AD, which suggests that abnormal amyloid generation is a triggering, initiating, or driving event in the disease cascade (1).”
BackgroundSelf-citationRoberts, B. R., Lind, M., Wagen, A. Z., Rembach, A., Frugier, T., Li, Q.-X., Ryan, T. M., McLean, C. A., Doecke, J. D., Rowe, C. C., et al. (2017) · Brain · doi:10.1093/brain/awx057 · Cited by 143
Braak, H., Zetterberg, H., Tredici, K. D., & Blennow, K. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1139-0 · Cited by 156
Advances in Alzheimer’s Diagnosis and Therapy: The Implications of Nanotechnology
Hajipour, M. J., Santoso, M. R., Rezaee, F., Aghaverdi, H., Mahmoudi, M., & Perry, G. (2017) · Trends in Biotechnology · doi:10.1016/j.tibtech.2017.06.002 · Cited by 143
Oxidative Stress in Aging-Matters of the Heart and Mind
Venkataraman, K., Khurana, S., & Tai, T. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140917897 · Cited by 142
“The hypothesis has evolved over the past 25 years to basically suggest that deposition of Aβ in brain parenchyma as a downstream result of aberrant cleavage of its precursor protein, APP, either due to mutations in APP or due to mutations in AD-associated presenilin genes, PSEN1 and 2, leads to neurofibrillary tangles…”
BackgroundBhattacharya, S., Haertel, C., Maelicke, A., & Montag, D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089454 · Cited by 142
“The amyloid cascade theory provides a rationale for many features of the disease including the pathological markers, the phenotypes caused by autosomal dominant disease genes, and the risk conferred by the APOE gene status [1].”
Carradori, D., Balducci, C., Re, F., Brambilla, D., Droumaguet, B. L., Flores, O., Gaudin, A., Mura, S., Forloni, G., Ordóñez‐Gutiérrez, L., et al. (2017) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2017.12.006 · Cited by 150
Pillaiyar, T., Meenakshisundaram, S., Manickam, M., & Sankaranarayanan, M. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112275 · Cited by 140
“neurochemical changes in the brain, are the crucial pathological event for AD [137].”
Monteiro-Cardoso, V. F., Oliveira, M. M., Melo, T., Domingues, M. R. M., Moreira, P. I., Ferreiro, E., Peixoto, F., & Videira, R. A. (2014) · Journal of Alzheimer’s Disease · doi:10.3233/jad-141002 · Cited by 140
“: +351 259350273; Fax: +351 259 350 480; E-mail: rvideira@utad.pt.”
Reconsideration of Anticholinesterase Therapeutic Strategies against Alzheimer’s Disease
Wang, H., & Zhang, H. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00391 · Cited by 136
Wu, W., Ji, Y., Wang, Z., Wu, X., Li, J., Gu, F., Chen, Z., & Wang, Z. (2023) · European journal of medical research · doi:10.1186/s40001-023-01512-w · Cited by 165
“It may also induce downstream lesions, such as tau phosphorylation and aggregation, leading to neuronal death in AD [2, 4–8].”
BackgroundGamma Secretase Modulators: New Alzheimer’s Drugs on the Horizon?
Bursavich, M. G., Harrison, B. A., & Blain, J.-F. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01960 · Cited by 137
Stabilizing ER Ca2+ Channel Function as an Early Preventative Strategy for Alzheimer’s Disease
Chakroborty, S., Briggs, C., Miller, M. B., Goussakov, I., Schneider, C., Kim, J., Wicks, J., Richardson, J. C., Conklin, V., Cameransi, B. G., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052056 · Cited by 138
“Recent clinical trials based on the amyloid hypothesis [1] have unfortunately failed to provide therapeutic opportunities [2–5].”
Hochgräfe, K., Sydow, A., Matenia, D., Cadinu, D., Könen, S., Petrova, O., Pickhardt, M., Goll, P., Morellini, F., Mandelkow, E., et al. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0204-4 · Cited by 137
“Recently, a number of promising drug candidates targeting different stages of Aβ pathology failed in clinical trials [3,4].”
BackgroundDrug development for alzheimer’s disease: Microglia induced neuroinflammation as a target
Dong, Y., Li, X., Cheng, J., & Hou, L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030558 · Cited by 136
“In the amyloid cascade hypothesis, senile plaques aggregation at the extracellular region of the human brain is responsible for an amyloid neurotoxic cascade, resulting in the atrophy and degeneration in the temporal and parietal lobe, pre-frontal cortex, and hippocampus, thus causing memory and cognitive impairment,…”
BackgroundAndo, K., Brion, J.-P., Stygelbout, V., Suain, V., Authelet, M., Dedecker, R., Chanut, A., Lacor, P., Lavaur, J., Sazdovitch, V., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1111-z · Cited by 136
“While increased Ab production is the mechanism in probably all FAD cases, decreased amyloid clearance could be involved in LOAD [35].”
BackgroundDementia risk and prevention by targeting modifiable vascular risk factors
Tariq, S., & Barber, P. A. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14132 · Cited by 136
“Quite simply, drugs are administered too late (Karran et al. 2011; Doody et al. 2013; Vellas et al. 2013) most likely because by the time the earliest symptoms appear, substantial and irreversible synaptic and neuronal loss has already occurred in critical brain regions (G omez-Isla et al. 1996;…”
BackgroundIn Vivo Applications of Single Chain Fv (Variable Domain) (scFv) Fragments
Monnier, P., Vigouroux, R. J., & Tassew, N. (2013) · Antibodies · doi:10.3390/antib2020193 · Cited by 122
“The 4 kDa A peptide resulting from the cleavage of the amyloid precursor protein is considered a potential target for AD therapy [61].”
BackgroundN -glycan and Alzheimer's disease
Kizuka, Y., Kitazume, S., & Taniguchi, N. (2017) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2017.04.012 · Cited by 141
Akyol, S., Ugur, Z., Yilmaz, A., Ustun, I., Gorti, S. K. K., Oh, K., McGuinness, B., Passmore, P., Kehoe, P. G., Maddens, M. E., et al. (2021) · Cells · doi:10.3390/cells10102591 · Cited by 134
“The accumulation of β-amyloid (Aβ) plaques and neurofibrillary tangles are considered classical hallmarks of AD pathology [5].”
BackgroundKostylev, M. A., Kaufman, A. C., Nygaard, H. B., Patel, P., Haas, L. T., Gunther, E. C., Vortmeyer, A., & Strittmatter, S. M. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.643577 · Cited by 133
“Such concordance between various A metrics could be explained by the existence of dynamic equilibrium between A species, a view widely acknowledged in the field (6, 10, 83, 84).”
BackgroundRamanan, V. K., Risacher, S. L., Nho, K., Kim, S., Shen, L., McDonald, B. C., Yoder, K. K., Hutchins, G. D., West, J. D., Tallman, E. F., et al. (2015) · Brain · doi:10.1093/brain/awv231 · Cited by 133
“Deposition of amyloid-b in the brain is thought to be a necessary early step in the development of Alzheimer’s disease, a progressive and highly prevalent neurodegenerative disorder with substantial societal burdens (Karran et al., 2011; Jack et al., 2013a).”
Backgroundβ-Amyloid and the Pathomechanisms of Alzheimer’s Disease: A Comprehensive View
Penke, B., Bogár, F., & Fülöp, L. (2017) · Molecules · doi:10.3390/molecules22101692 · Cited by 132
“Up to now, most of the strategies have failed in clinical trials and the relevance of the amyloid hypothesis has often been questioned [16].”
BackgroundGenome-wide meta-analysis for Alzheimer’s disease cerebrospinal fluid biomarkers
Jansen, I. E., van der Lee, S. J., Gomez-Fonseca, D., de Rojas, I., Dalmasso, M. C., Grenier-Boley, B., Zettergren, A., Mishra, A., Ali, M., Andrade, V., et al. (2022) · Acta Neuropathologica · doi:10.1007/s00401-022-02454-z · Cited by 132
“Resolving the genetic background of Alzheimer’s disease (AD) has proven to contribute greatly to our understanding of underlying disease processes, for instance with the discovery of APP [25], PSEN1 [53], and PSEN2 [52] in family-based studies, leading to the amyloid cascade theory [38].”
BackgroundEketjäll, S., Janson, J., Kaspersson, K., Bogstedt, A., Jeppsson, F., Fälting, J., Haeberlein, S. B., Kugler, A. R., Alexander, R. C., & Cebers, G. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150834 · Cited by 132
“Modulation of A production or clearance is, therefore, considered one of the highest priority targets for disease modification in AD [6].”
Background3D culture models of Alzheimer’s disease: a road map to a “cure-in-a-dish”
Choi, S. H., Kim, Y. H., Quinti, L., Tanzi, R. E., & Kim, D. Y. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0139-7 · Cited by 132
Wilkaniec, A., Gąssowska-Dobrowolska, M., Strawski, M., Adamczyk, A., & Czapski, G. A. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-017-1027-y · Cited by 131
When Does Alzheimer′s Disease Really Start? The Role of Biomarkers
Lloret, A., Esteve, D., Lloret, M.-A., Cervera-Ferri, A., Lopez, B., Nepomuceno, M., & Monllor, P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225536 · Cited by 131
“This could be due to differences in the processing of Aβ, to the capacity of resistance to pathological damage derived from the toxicity of Aβ and to compensatory mechanisms [106].”
BackgroundThe Lipoxygenases: Their Regulation and Implication in Alzheimer’s Disease
Czapski, G. A., Czubowicz, K., Strosznajder, J. B., & Strosznajder, R. P. (2016) · Neurochemical Research · doi:10.1007/s11064-015-1776-x · Cited by 131
Synaptic dysfunction and septin protein family members in neurodegenerative diseases
Marttinen, M., Kurkinen, K. M., Soininen, H., Haapasalo, A., & Hiltunen, M. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0013-z · Cited by 130
“Despite the well-established foundation of the amyloid cascade hypothesis, the reported Aβ-targeted trials in AD patients to date have not been successful [27].”
BackgroundBiometals and Their Therapeutic Implications in Alzheimer's Disease
Ayton, S., Lei, P., & Bush, A. I. (2014) · Neurotherapeutics · doi:10.1007/s13311-014-0312-z · Cited by 141
“review see [33]).”
The role of copper ions in pathophysiology and fluorescent sensors for the detection thereof
Verwilst, P., Sunwoo, K., & Kim, J. S. (2015) · Chemical Communications · doi:10.1039/c4cc10366a · Cited by 139
Pujadas, L., Rossi, D., Andrés, R., Teixeira, C. M., Serra-Vidal, B., Parcerisas, A., Maldonado, R., Giralt, E., Carulla, N., & Soriano, E. (2014) · Nature Communications · doi:10.1038/ncomms4443 · Cited by 129
Sex dimorphism profile of Alzheimer’s disease-type pathologies in an APP/PS1 mouse model
Jiao, S.-S., Bu, X.-L., Liu, Y.-H., Zhu, C., Wang, Q.-H., Shen, L.-L., Liu, C.-H., Wang, Y.-R., Yao, X.-Q., & Wang, Y.-J. (2016) · Neurotoxicity Research · doi:10.1007/s12640-015-9589-x · Cited by 129
“The toxicity of Ab species varies according to aggregating status, with soluble Ab oligomers being the most toxic (Karran et al. 2011; Benilova et al. 2012; Hardy and Selkoe 2002).”
Noninvasive 40-hz light flicker to recruit microglia and reduce amyloid beta load
Singer, A. C., Martorell, A. J., Douglas, J. M., Abdurrob, F., Attokaren, M. K., Tipton, J., Mathys, H., Adaikkan, C., & Tsai, L.-H. (2018) · Nature Protocols · doi:10.1038/s41596-018-0021-x · Cited by 127
Yu, L., Wang, S., Chen, X., Yang, H., Li, X., Xu, Y., & Zhu, X. (2015) · Life Sciences · doi:10.1016/j.lfs.2014.11.021 · Cited by 136
“Although the precise mechanism of AD is still unknown, increasing evidence indicates that Aβ-induced toxicity and oxidative stress in the brain are the key events in its pathogenesis [8,10,15].”
Gao, J., Zhou, R., You, X., Luo, F., He, H., Chang, X., Zhu, L., Ding, X., & Yan, T. (2016) · Metabolic Brain Disease · doi:10.1007/s11011-016-9813-2 · Cited by 130
Antiamyloid Therapy for Alzheimer's Disease — Are We on the Right Road?
Karran, E., & Hardy, J. (2014) · New England Journal of Medicine · doi:10.1056/nejme1313943 · Cited by 126
Self-citationMateriomics: An ‐omics Approach to Biomaterials Research
Cranford, S. W., de Boer, J., van Blitterswijk, C., & Buehler, M. J. (2013) · Advanced Materials · doi:10.1002/adma.201202553 · Cited by 146
Metadata
- Authors
- Karran, E., Mercken, M., & Strooper, B. D.
- Affiliations
- Janssen (Belgium) (BE)
- Vlaams Instituut voor Biotechnologie (BE)
- Corresponding author
- Karran, Eric
- Venue
- Nature Reviews Drug Discovery
- Published
- 2011-08-19
- Volume
- 10
- Issue
- 9
- Pages
- 698-712
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2079749054
- Cited by
- 2,188
- References
- 157
- Citations by year
- 2026: 74 · 2025: 115 · 2024: 130 · 2023: 139 · 2022: 141 · 2021: 158 · 2020: 174 · 2019: 191 · 2018: 174 · 2017: 163 · 2016: 171 · 2015: 160 · 2014: 151 · 2013: 130 · 2012: 107
- FWCI
- 13.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- amyloid hypothesis, Alzheimer's disease, amyloid-beta, amyloid-beta aggregation, amyloid-beta production, clinical trial design, phase III trial failure, drug development
- MeSH terms
- Alzheimer Disease, Animals, Brain Chemistry, Humans, Research Design, Amyloid beta-Peptides, Treatment Failure, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Age of Onset, Disease Progression, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.